[Observations on the length of stay of psoriasis patients in relation to different therapeutic procedures and in particular to combined therapeutic procedure: triamcinolone, antidiabetic sulfonamides and protein anabolic agents].
D045930:Anabolic Agents; D000715:Anatomy; D003131:Combined Modality Therapy; D003907:Dexamethasone; D006801:Humans; D007004:Hypoglycemic Agents; D007902:Length of Stay; D011241:Prednisone; D011565:Psoriasis; D000077145:Sulfanilamide; D013424:Sulfanilamides; D013449:Sulfonamides; D014221:Triamcinolone; D014222:Triamcinolone Acetonide
D045930:Anabolic Agents; D007004:Hypoglycemic Agents; D013424:Sulfanilamides; D013449:Sulfonamides; D014221:Triamcinolone; D000077145:Sulfanilamide; D003907:Dexamethasone; D014222:Triamcinolone Acetonide; D011241:Prednisone
ANATOMY; ANTIDIABETICS; DEXAMETHASONE; PREDNISONE; PSORIASIS; TRIAMCINOLONE ACETONIDE